Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

NLM Logo

Canagliflozin MeSH Descriptor Data 2025


MeSH Heading
Canagliflozin
Tree Number(s)
D02.886.778.075
D03.383.903.075
D09.408.348.113
Unique ID
D000068896
RDF Unique Identifier
http://id.nlm.nih.gov/mesh/D000068896
Scope Note
A glucoside-derived SODIUM-GLUCOSE TRANSPORTER 2 inhibitor that stimulates urinary excretion of glucose by suppressing renal glucose reabsorption. It is used to manage BLOOD GLUCOSE levels in patients with TYPE 2 DIABETES.
Entry Term(s)
1-(Glucopyranosyl)-4-methyl-3-(5-(4-fluorophenyl)-2-thienylmethyl)benzene - T777973
Canagliflozin Hemihydrate
Canagliflozin, Anhydrous
Invokana
Pharm Action
Sodium-Glucose Transporter 2 Inhibitors
Registry Numbers
0SAC974Z85
0
6S49DGR869
Related Numbers
6S49DGR869
928672-86-0
Public MeSH Note
2016; CANAGLIFLOZIN was indexed under GLUCOSIDES and THIOPHENES 2014-2015
History Note
2016 (2014)
Date Established
2016/01/01
Date of Entry
2015/07/01
Revision Date
2018/02/28
Canagliflozin Preferred
Invokana Narrower
Canagliflozin, Anhydrous Related
Canagliflozin Hemihydrate Narrower
page delivered in 0.12s